Literature DB >> 1261153

Spironolactone. I. Disposition and metabolism.

A Karim, J Zagarella, J Hribar, M Dooley.   

Abstract

This study describes absorption, excretion, and metabolism of[20(-3)H]-spironolactone (SP) in 5 healthy men. After a single oral dose (200 mg + 200 muCi) of the drug given in alcoholic solution, the peak serum levels of the ethyl acetate-extractable tritium and the dethioacetylated metabolite canrenone were 763 +/- 400 ng/ml (mean +/- SD) and 415 +/- 145 ng/ml, respectively. These levels occurred within 3 hr. The serum half-life (T1/2) of the extractable materials was 37.3 +/- 6.53 hr. Canrenone levels declined in two phases. The T1/2 from 2.5 to 12 hr was 4.42 +/- 1.07 hr and from 12 to 72 hr was 16.8 +/- 2.75 hr. In the blood both SP and canrenone were confined largely in the plasma, and their protein binding exceeded 89% at concentrations of 550 and 710 ng/ml, respectively. In 5 days 31.6 +/- 5.87% of the radioactivity was excreted in the urine and 22.7 +/- 14.1% in the feces. Unchanged SP was not detected in the urine. The major urinary metabolites were canrenone (5.04 +/- 2.83% of dose), 6beta-OH-sulfoxide (5.21 +/- 0.93% of dose), and canrenoate ester glucuronide (6.2% of dose).

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1261153     DOI: 10.1002/cpt1976192158

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  20 in total

1.  Canrenoate disposition in dogs. Tissue distribution and elimination.

Authors:  J Kuhlmann; V Kötter; N Rietbrock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-06       Impact factor: 3.000

2.  Pharmacokinetics of the new aldosterone antagonist, spirorenone, in healthy volunteers after single and repeated daily doses.

Authors:  W Krause; C Sack; W Seifert
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone.

Authors:  P C Ho; D W Bourne; E J Triggs; B A Smithurst
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Spironolactone and diabetic ketoacidosis.

Authors:  A G Jariwalla; C R Jones; A Lever; R Hall
Journal:  Postgrad Med J       Date:  1981-09       Impact factor: 2.401

5.  Systolic time intervals during spironolactone treatment of digitalized and non-digitalized patients with ischaemic heart disease.

Authors:  S Waldorff; J Berning; J Buch; E Steiness
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Comparison of prorenoate potassium and spironolactone after repeated doses and steady state plasma levels of active metabolites.

Authors:  G T McInnes; J R Shelton; I R Harrison; R M Perkins; R F Palmer
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

7.  Relative potency of prorenoate potassium and spironolactone in attenuating diuretic induced hypokalaemia.

Authors:  G T McInnes; I R Harrison; J R Shelton; R M Perkins; J M Clarke
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of diuretics.

Authors:  B Beermann; M Groschinsky-Grind
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

9.  Improved method for comparative evaluation of aldosterone antagonists in healthy man.

Authors:  J Casals-Stenzel; J Schmalbach; W Losert
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

10.  Spironolactone dose-response relationships in healthy subjects.

Authors:  G T McInnes; R M Perkins; J R Shelton; I R Harrison
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.